Shengshuang Zhu
Senior Principal Scientist Arbor Biotech
Dr. Zhu has been working on novel nucleic acid delivery technology and formulation for the past decade. He is currently a Senior Principal Scientist at Arbor Biotechnologies leading the non-viral delivery effort from discovery to translation. Prior to Arbor, Dr. Zhu worked at Eli Lilly, where he established Lilly’s internal lipid nanoparticle production workstream and led the clinical translation of Lilly’s very first siRNA asset. Prior to Lilly, he invented multiple critical DNA delivery technologies to target extrahepatic tissues for the treatment and diagnostics of cancer. As a professional drug developer, he has been the key contributor for three genetic medicine programs that are dosing patients in global clinical trials. His work has been published on high impact journals such as JACS, Advanced Materials, ACS and resulted in multiple patents. Dr. Zhu obtained his Ph.D in Materials Science and Engineering from Northwestern with Professor Chad Mirkin.
Seminars
- Uncovering the origins of LNP technology and how they were initially discovered
- Exploring the evolving role of LNPs from early gene delivery systems to their pivotal role in mRNA vaccine development
- Showcasing the key scientific breakthroughs that have shaped modern LNP design
